Competition & Peer Data API & CSV Delivery Connect to AI Assistant via MCP

Regentis Biomaterials Ltd's Competitiveness

Name: Regentis Biomaterials Ltd Competitors and Peer Comparison
Creator: CSIMarket
License: https://csimarket.com/help/terms-of-use

A competitive positioning analysis and financial ratio benchmarking of Regentis Biomaterials Ltd (RGNT) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.

Peer Data As of Q4 2025

API endpoints for this dataset

                        https://api.csimarket.com/api/v1/companies/RGNT/competitors                    

                        https://api.csimarket.com/api/v1/companies/RGNT/relationships                    

                        https://api.csimarket.com/api/v1/companies/RGNT/similar                    

Programmatic access for models, analytics, and integration workflows.

Pull these exact ratios programmatically

Get an API key License this feed for redistribution / AI →

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

AI Integration via MCP

Connect Claude, ChatGPT, or any MCP-compatible AI assistant directly to this data.

Regentis Biomaterials Ltd's Competitor Quality Breadth

Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).

Entity	Profitable	Expanding	Above Industry Growth	Distressed
Regentis Biomaterials Ltd	-	-	-	Yes
High-Confidence Competitors (3)
Similar-Size Competitors (10)

Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.

RGNT Stock Performance relative to its Competitors

RGNT Competitors (weighted) Percent change over the selected range

Regentis Biomaterials Ltd's Share Price Performance vs Peer Groups

Trailing 12-month total share price return, and the share of each group that outperformed the U.S.A. 500 over the same period. Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC.

High-Confidence
(1 of 2)

Similar-Size
(0 of 5)

Entity	TTM Share Price Return (group: median)	vs U.S.A. 500
Regentis Biomaterials Ltd	-	-
Competitors combined (0)	40.4%	63.2%
High-Confidence Competitors (2)	40.4%	63.2%
Similar-Size Competitors (5)	40.4%	63.2%
Similar Growth & Profitability (0)	40.4%	63.2%

Peer Group Share Price Returns

TTM share price return and U.S.A. 500 outperformance for Regentis Biomaterials Ltd's competitor groups requires a Commercial License.

Unlock Commercial Access

Source: CSIMarket API (daily market-structure computation). Outperformance is trailing-12-month total return vs the U.S.A. 500 over the same window, not risk-adjusted.

RGNT Stock Performance relative to High-Confidence Competitors

RGNT High-Confidence Competitors (equal-weighted, 3) Percent change over the selected range

RGNT Stock Performance relative to Similar-Size Competitors

RGNT Similar-Size Competitors (equal-weighted, 10) Percent change over the selected range

Regentis Biomaterials Ltd's Comment on Competition and Industry Peers

The competitive landscape for cartilage repair products includes Vericel Corp., Arthrex GmbH, ISTO Technologies Inc., and CartiHeal, which was acquired by Smith & Nephew in January 2024. Vericel Corp. offers autologous chondrocyte implantation treatments and is the only commercial provider in the U.S. market. Arthrex GmbH markets BioCartilage, a paste combined with platelet-rich plasma or minced cartilage tissue. ISTO Technologies Inc. offers Revaflex, a diced cadaver cartilage product. These competitors utilize cadaver tissue and have limited use across the patient population. Based on revenue, procedure volume, and market presence, these competitors do not hold a significant market share in cartilage repair. Additional potential competitors are in early research and development stages and have not yet received marketing approval, leaving their market impact uncertain.

Competitor data is not yet available for Regentis Biomaterials Ltd.

Regentis Biomaterials Ltd's Competitors Named by the Company

Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.

Competitor	Basis	Confidence	Active	Sources
Arthrex GmbH	Named by the company	85%	2022 to 2026	3
Smith & Nephew	Named by the company	85%	2022 to 2026	3
CartiHeal	Named by the company	85%	2022 to 2026	3
Oceantech Acquisitions I Corp	Named by the company	85%	2022 to 2026	3
Vericel Corp.	Named by the company	85%	2022 to 2026	3
ISTO Technologies Inc.	Named by the company	85%	2022 to 2026	3

Competitor Evidence Detail

Filing basis, confidence, active dates and source counts for Regentis Biomaterials Ltd's named competitors require a Commercial License.

Unlock Commercial Access

Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.